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In the last few years, we observed many developments about Lyme disease, especially in microbiological, clinical
and therapeutical research fields.
We better understood the mechanisms through which Borrelia protects itself from human immune system and new
species of Borrelia related to Lyme disease have been identified [1 - 10].
Focusing  on  clinical  aspects,  new  correlations  between  Lyme  and  other  diseases  have  been  reported,  such  as
Cutaneous Marginal Zone B-cell Lymphomas, recalling Mucosa Associated Lymphoid Tissue Lymphoma caused by
Helicobacter pylori [11 - 14]. Atrophosclerodermic diseases related to Lyme disease, such as morphea, lichen sclerosus
et  atrophicus  and  Parry-Romberg  hemiatrophy,  still  remain  debated  [15  -  29].  Neuroborelliosis  is  still  a  frequent
challenging manifestation both for diagnosis and for treatment [30 - 33].
In some areas of the world, like in Brazil and the Amazon rainforest, Lyme disease can show a peculiar feature
associated with autoimmune rections, perhaps due to the transmission of Borrelia by Amblyomma sp. Instead of Ixodes
complex ticks (Baggio-Yoshinari Syndrome) [34].
In the therapeutic management it is important also to document the possible co-infection by Ehrlichia (Anaplasma
phagocytophilum in Europe), Rickettsia spp, Bartonella spp and Babesia (microti in USA, divergens and venatorum in
Europe),  especially  when  the  clinical  manifestions  are  atypical  [35,  36].  Lyme  disease,  in  some  cases,  combines
infectious,  immunological  and  proliferative  aspects,  becoming  an  entity  difficult  to  recognize,  treat  and  manage.
Treatment of Lyme disease follows the traditional guidelines for early and late Borreliosis, while in the resistant forms
the use of some other drugs such as metronidazole or hydroxychloroquine is on discussion [37, 38].
Fortunately  Borrelia  infection  is  mostly  recognized  early  (erythema  migrans)  and  antibiotic  treatment  with
amoxicilline  or  doxycycline  almost  always  leads  to  heal  but  complicated  cases  are  often  diagnosed  too  late.
ORGANIZATION OF THE VOLUME
At the beginning of this special issue we report the contributions that deal with Borrelia genotyping (Eva Ružić-
Sabljić) and the epidemiology of Lyme disease in domestic and wild animals (Vittorio Sala). After providing an update
on microbiology we analyze clinical aspects focusing on atrophosclerodermic manifestations (Elisabeth Aberer) and
nervous system involvement in Lyme borreliosis (Vera Maraspin). We report the impact of co-infections (Giuseppe
Stinco) and a review of diagnostic tools for Borrelia assessment in humans (Serena Bonin) before concluding with the
issue of therapy (Giusto Trevisan).
In the first article Eva Ružić-Sabljić and Cerar Tjaša describe Borrelia genotyping. Borrelia burgdorferi sensu lato
is the causative agent of Lyme borreliosis while different borrelia species can lead to distinct clinical presentations and
some species are associated with defined clinical manifestation like Borrelia afzelii with skin manifestations, Borrelia
garinii with central nervous system disorders and Borrelia burgdorferi sensu stricto with Lyme arthritis. Genotyping of
Borrelia strains is of great importance for epidemiological, clinical, and evolutionary studies. The authors review the
different typing methods that recently have been implemented more or less successfully for diagnostic purposes.
In  the  second  contribution  Vittorio  Sala  and  Eleonora  De  Faveri  review  the  main  aspects  of  Lyme  Borreliosis
epidemiology in animals (domestic and wild) and ticks. In particular, the environmental interference on the interactions
between different hosts, including humans as terminal host are focused. The authors analyze the species of ticks and the
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prevalence of Borrelia  species in the diverse continents.  The function of the reservoirs animal is also different and
depends on the belonging species. As the climatic variations and the changes in the duration of seasons interfere with
the biological cycles of the animal species, arthropods and bacteria, a gradual change occurs in the epidemiology of the
infection and of the clinical evidence of the disease in different animal species and humans. Finally, the implications of
Lyme disease in the field of social health have been considered.
Focusing  on  clinical  aspects,  in  the  third  article,  Elisabeth  Aberer  and  Nora  Wutte  summarize  the  literature  on
scleratrophic skin lesions as a manifestation of a Borrelia infection. An association of morphea, acrodermatitis chronica
atrophicans, lichen sclerosus et atrophicus and anetoderma have been observed. Since all these diseases show clinical
and histological similarities, it has been hypothesised that they might have a common origin. The laboratory results that
point to a borrelial origin of these diseases, however, are contradictory. The response of scleratrophic skin lesions to
antibiotic treatment varies and can be seen in patients with or without a proven association to a Borrelia infection. This
suggests that scleratrophic diseases might be of heterogeneous origin, but a Borrelia infection could be one cause of
these dermatoses.
As second contribution on clinical update, Vera Maraspin and Katarina Ogrinc review neurological manifestations
in Lyme disease. Lyme neuroborreliosis is the second most frequent manifestation of Lyme borreliosis in Europe, while
it  comprises  the  third  most  common expression  of  the  disease  in  North  America.  The  authors  review the  different
feature  of  early  Lyme  neuroborreliosis,  in  Europe  (with  the  classical  triad  of  meningitis,  radiculoneuritis,  cranial
neuropathy)  and  in  America  (with  subacute  meningitis  with  or  without  cranial  neurophaty),  and  the  chronic  forms
(peripheral neuritis with acrodermatitis chronica atrophicans). In this article, the challenging diagnosis and antibiotic
treatment of neuroborreliosis are analyzed.
In the fifth contribution, Giuseppe Stinco and Serena Bergamo analyze the impact of co-infections in Lyme disease.
In the recent years co-infections emerged as an important issue in Lyme disease spectrum. In this review the association
of Borrelia infection and Anaplasma phagocytophilum, Babesia spp , Bartonella spp, Rickettsiae spp and tick-borne
encephalitis  virus  is  reported.  For  each  single  co-infecting  micro-organism,  clinical  features,  diagnostic  issues  and
therapeutical approaches are discussed. They might exacerbate Lyme disease clinical features,  they can also mimic
Lyme borreliosis sharing common manifestations, and eventually they can change the course of the disease itself. The
presence of one or more co-infecting agent during the course of Lyme disease may represent an issue especially in
endemic areas for tick-borne diseases and in people occupationally exposed.
The  sixth  chapter  is  dedicated  to  diagnostic  tools  in  assessment  of  Lyme  disease  described  by  Serena  Bonin.
Although the etiological agent has been known since 1980s, diagnosis of Lyme disease is still a controversial topic
because of the wide range of clinical manifestations and the limited diagnostic tools available to assess Borrelia  in
humans.  The most  used diagnostic  tool  for  Lyme disease is  currently serology,  but  also Polymerase chain reaction
(PCR) and other methods are often used to prove Borrelia infection in different patients’ specimens. The present article
deals with most of the diagnostic tools used in clinical practice for Lyme disease detection in human samples. Direct
and indirect specific methods for Borrelia  infection detection is discussed. The author analyse the most recent peer
reviewed publications as well as original results and information provided by companies’ web sites.
After etiological, epidemiological, clinical and diagnostic issues, the last article is dedicated to the therapy of Lyme
disease reviewed by Giusto Trevisan. Borrelia burgdorferi is highly susceptible to antibiotic treatment and the majority
of patients profit from this treatment. Antibiotic selection, dose and route of administration, and duration of therapy for
Lyme disease depend on the patient’s clinical manifestations and stage of disease, age, pregnancy status, as well as the
presence of other concomitant diseases and/or allergies. Despite an appropriate antibiotic therapy, about 10-20% of
patients may show persistent or recurrent symptoms ("post-treatment Lyme disease syndrome").
The author discusses on the post-exposure prophylaxis, the current therapeutic approach, the main treatment-related
phenomenon, the Jarisch-Herxheimer reaction, and the treatment modalities for special categories of patients.
In sum, we hope that the present paper presented in this special issue constitute a useful reference for researchers as
well as for daily practice in the domain of Lyme disease.
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